What Causes High-Grade Glioma (Glioblastoma)?
The cause of most high-grade gliomas remains unknown, but exposure to ionizing radiation is the only definitively established environmental risk factor, while rare hereditary cancer syndromes (neurofibromatosis type 1, Li-Fraumeni syndrome, Turcot/Lynch syndrome) account for a small subset of cases. 1
Established Risk Factors
Environmental Exposures
Ionizing Radiation is the only confirmed environmental cause:
- Therapeutic radiation exposure increases glioma risk with a latency period of 7-9 years 2
- Risk is higher in younger children due to increased radiosensitivity 2
- Radiation-induced gliomas and meningiomas are the most common secondary brain tumors following cranial irradiation 2
Cell phone use has NOT been confirmed as a risk factor in epidemiological studies 1
Hereditary Syndromes
Rare genetic syndromes carry substantially increased risk 1, 2:
- Neurofibromatosis type 1
- Li-Fraumeni syndrome (TP53 germline mutations)
- Turcot syndrome/Lynch syndrome/Constitutional Mismatch Repair Deficiency (CMMRD)
- Cowden syndrome
These hereditary cases represent a small minority of all high-grade gliomas but should prompt genetic counseling and cancer predisposition evaluation 2.
Molecular Pathogenesis
Primary vs. Secondary Glioblastoma
High-grade gliomas develop through two distinct pathways 1:
Primary (de novo) Glioblastoma (~90% of cases):
- IDH wild-type
- Develops rapidly without evidence of lower-grade precursor
- Associated with EGFR amplification, TERT promoter mutations, +7/-10 chromosomal signature
- Worse prognosis
Secondary Glioblastoma (~10% of cases):
- IDH-mutant (IDH1 or IDH2)
- Evolves from lower-grade precursor lesions (grade 2 or 3 gliomas)
- Better prognosis than IDH wild-type tumors
- More common in younger patients
Key Molecular Alterations
The molecular mechanisms involve deregulation of multiple pathways 3:
- Growth factor signaling (EGFR, PDGFRA alterations)
- Cell cycle control (p16-CDK4-RB pathway disruption)
- Tumor suppressor pathways (ARF-MDM2-p53 pathway alterations)
- DNA repair mechanisms (MGMT promoter methylation status)
Epidemiologic Patterns
- Incidence: 3-5 per 100,000 population annually 1
- Age: Peak incidence in fifth and sixth decades of life 1
- Sex: Slight male predominance; males have higher mortality rates 2
- Pediatric cases: Different molecular profiles with H3 mutations (H3 K27-altered, H3 G34-mutant) and fusion genes (ALK, ROS1, NTRK1/2/3, MET) 2
Clinical Implications
Risk Stratification
Patients with hereditary syndromes require:
- Enhanced surveillance protocols
- Genetic counseling for family members
- Modified treatment approaches (radiation may be contraindicated in some syndromes due to increased secondary malignancy risk)
Protective Factors
History of allergies or atopic diseases has been associated with decreased risk of glioma 4, though the mechanism remains unclear.
Unproven Associations
Occupational exposures have been examined but remain inconclusive 4. Most proposed environmental factors lack sufficient evidence to establish causation.
Important Caveats
- The vast majority of glioblastomas are sporadic with no identifiable cause 2
- Cellular origin remains debated (neural stem cells, astrocytes, or oligodendrocyte precursor cells may all serve as cells of origin) 5
- Therapy-related high-grade gliomas can develop after treatment for other primary CNS tumors, involving complex interplay of radiation, chemotherapy, and genetic susceptibility 6
- The median latency for radiation-induced gliomas is approximately 6 years (range 2-9 years) 6